MedDataX Logo

Hsv 1 and 2 Gowey Protocol Versus Placebo

NCT ID: NCT01477879

Last Updated: 2011-11-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare efficacy of versabase gel with 20% sarracenia purpurea versus placebo applied every 3-4 hours to herpes lesions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients screened for hsv one or two. Patients with herpes given a 1/8 oz of gel. Researcher does not know which is active and which is placebo (placebo is actually just versabase gel). Patent applies gel to lesions every 3-4 hours. Returns to clinic on days 3, 5, and 14 for evaluation. Up to 50 patients may be enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Herpes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Versabase/20% S. purpurea extract

Group Type ACTIVE_COMPARATOR

Versabase gel with sarracenia purpurea 20% liquid extract

Intervention Type OTHER

Topical application of gel/plant mix to lesions

placebo (versabase gel only)

placebo used will be versabase gel alone

Group Type PLACEBO_COMPARATOR

placebo (versabase gel only)

Intervention Type OTHER

versabase gel only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Versabase gel with sarracenia purpurea 20% liquid extract

Topical application of gel/plant mix to lesions

Intervention Type OTHER

placebo (versabase gel only)

versabase gel only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Hsv 1\&2

Exclusion Criteria

* No active lesions
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Naturopaths International

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Brandie Gowey, NMD

Brandie Gowey

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Naturopaths international

Flagstaff, Arizona, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSV1&2

Identifier Type: -

Identifier Source: org_study_id